The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes

Ellipticines as DNA-Targeted Chemotherapeutics

(2014) Marie Stiborova et al.   CURRENT MEDICINAL CHEMISTRY

Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells

(2014) E. G. Russell et al.   INVESTIGATIONAL NEW DRUGS

Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage

(2014) Cecilia Savorani et al.   LEUKEMIA & LYMPHOMA

Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions

(2014) Marie Stiborová et al.   TOXICOLOGY

Ellipticine Binds to a Human Telomere Sequence: An Additional Mode of Action as a Putative Anticancer Agent?

(2013) Saptaparni Ghosh et al.   BIOCHEMISTRY

Old Drug, New Target

(2013) William J. Andrews et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cytochrome b5 Increases Cytochrome P450 3A4-Mediated Activation of Anticancer Drug Ellipticine to 13-Hydroxyellipticine Whose Covalent Binding to DNA Is Elevated by Sulfotransferases and N,O-Acetyltransferases

(2012) Marie Stiborová et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Contributions of Human Enzymes in Carcinogen Metabolism

(2012) Slobodan Rendic et al.   CHEMICAL RESEARCH IN TOXICOLOGY

The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment

(2012) M. Stiborova et al.   CURRENT MEDICINAL CHEMISTRY

Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5

(2012) Marie Stiborová et al.   TOXICOLOGY

Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling

(2012) Volker M. Arlt et al.   TOXICOLOGY LETTERS

Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles

(2012) Charlotte M. Miller et al.   RSC Advances

Cytochrome b5 shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy

(2011) Věra Kotrbová et al.   BIOCHEMICAL PHARMACOLOGY

Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances

(2011) Rene Kizek et al.   PHARMACOLOGY & THERAPEUTICS

Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model

(2011) Kateřina Levová et al.   TOXICOLOGICAL SCIENCES

Ellipticine induces apoptosis in human endometrial cancer cells: The potential involvement of reactive oxygen species and mitogen-activated protein kinases

(2011) Ji Young Kim et al.   TOXICOLOGY

Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells

(2010) Fei Wang et al.   APOPTOSIS

Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency

(2010) M. Stiborová et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

α5β1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells

(2010) Eva Martinkova et al.   INTERNATIONAL JOURNAL OF CANCER

Glycosylation Protects Proteins against Free Radicals Generated from Toxic Xenobiotics

(2010) Václav Martínek et al.   TOXICOLOGICAL SCIENCES

The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells

(2009) Jitka Poljaková et al.   BIOCHEMICAL PHARMACOLOGY

Fatty Acid Hydroperoxides Support Cytochrome P450 2S1-Mediated Bioactivation of Benzo[a]pyrene-7,8-dihydrodiol

(2009) P. H. Bui et al.   MOLECULAR PHARMACOLOGY

Functional Characterization of Human Cytochrome P450 2S1 Using a Synthetic Gene-Expressed Protein in Escherichia coli

(2009) P. H. Bui et al.   MOLECULAR PHARMACOLOGY

Preparation of a biologically active apo-cytochrome b5 via heterologous expression in Escherichia coli

(2009) Věra Kotrbová et al.   PROTEIN EXPRESSION AND PURIFICATION

A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization

(2008) G. Wei Xu et al.   APOPTOSIS

Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer

(2008) H Lu et al.   CANCER GENE THERAPY

Defining thein VivoRole for Cytochromeb5in Cytochrome P450 Function through the Conditional Hepatic Deletion of Microsomal Cytochromeb5

(2008) Robert D. Finn et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity

(2008) Y. Xiao et al.   KIDNEY INTERNATIONAL

RETRACTED: Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells

(2008) Kang Fang et al.   LUNG CANCER

Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: Studies with the hepatic NADPH:Cytochrome P450 reductase null mouse

(2007) Marie Stiborová et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY